Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Kingchem
301509
5
Hunan Er-kang Pharmaceutical
300267
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 70.14%271.13M | 100.86%98.22M | 71.28%69.96M | 60.20%55.97M | 35.49%46.98M | 26.91%159.36M | 27.76%48.9M | 34.32%40.84M | 19.44%34.94M | 25.47%34.67M |
Operating revenue | 70.14%271.13M | 100.86%98.22M | 71.28%69.96M | 60.20%55.97M | 35.49%46.98M | 26.91%159.36M | 27.76%48.9M | 34.32%40.84M | 19.44%34.94M | 25.47%34.67M |
Cost of revenue | 11.63%51.76M | 24.57%14.58M | 21.16%13.42M | 5.99%12.74M | -4.74%11.03M | -9.46%46.37M | 7.09%11.7M | -4.38%11.08M | -2.47%12.02M | -29.34%11.57M |
Gross profit | 94.16%219.36M | 124.86%83.64M | 89.93%56.53M | 88.62%43.23M | 55.65%35.95M | 51.95%112.98M | 36.02%37.2M | 58.14%29.77M | 35.38%22.92M | 105.25%23.1M |
Operating expense | 51.04%137.12M | 78.71%52.77M | 46.19%35.69M | 38.50%26.53M | 25.11%22.12M | -20.22%90.78M | 30.64%29.53M | 4.69%24.42M | -37.15%19.16M | -52.70%17.68M |
Selling and administrative expenses | 2.78%21.14M | 151.06%9.45M | -11.33%5.14M | -29.82%3.52M | -49.40%3.03M | -41.86%20.57M | -34.54%3.76M | -5.62%5.8M | -52.04%5.01M | -54.01%6M |
-Selling and marketing expense | -18.73%9.74M | 189.04%5.36M | -24.61%2.73M | -69.97%995.09K | -79.53%654.88K | -36.83%11.98M | -48.00%1.86M | -6.28%3.62M | -46.95%3.31M | -39.62%3.2M |
-General and administrative expense | 32.79%11.4M | 114.11%4.08M | 10.66%2.42M | 48.55%2.52M | -14.95%2.38M | -47.67%8.59M | -12.49%1.91M | -4.53%2.18M | -59.59%1.7M | -63.86%2.8M |
Provision for doubtful accounts | 137.27%55.01M | 131.74%24.38M | 130.69%15.4M | 134.94%10.09M | 203.36%5.14M | -21.23%23.19M | 94.78%10.52M | 17.55%6.68M | -45.55%4.3M | -83.81%1.69M |
Other operating expenses | 29.64%60.96M | 24.26%18.95M | 26.87%15.15M | 31.19%12.92M | 39.61%13.94M | -3.97%47.02M | 33.11%15.25M | 3.85%11.94M | -18.89%9.85M | -27.99%9.99M |
Operating profit | 270.47%82.25M | 302.62%30.87M | 289.57%20.84M | 343.74%16.7M | 155.26%13.83M | 156.30%22.2M | 61.68%7.67M | 218.87%5.35M | 127.77%3.76M | 120.75%5.42M |
Net non-operating interest income expense | 13.82%-13.76M | 23.78%-3.44M | 19.68%-3.33M | 25.99%-2.91M | -20.86%-4.08M | -85.66%-15.97M | -44.54%-4.51M | -89.02%-4.14M | -135.56%-3.93M | -109.06%-3.38M |
Non-operating interest expense | -13.82%13.76M | -23.78%3.44M | -19.68%3.33M | -25.99%2.91M | 20.86%4.08M | 85.66%15.97M | 44.54%4.51M | 89.02%4.14M | 135.56%3.93M | 109.06%3.38M |
Other net income (expense) | -178.97%-1.17M | -14.31%299.86K | -7.45%96.06K | -115.75%-209.58K | -341.17%-1.35M | -85.24%1.48M | 136.31%349.96K | -99.06%103.79K | 756.50%1.33M | -34.32%-306.71K |
Gain on sale of security | -176.68%-1.26M | --0 | ---- | ---- | -200.23%-1.26M | -1,004.26%-455.96K | ---376.69K | --89.23K | --251.71K | ---420.2K |
Special income (charges) | ---259.71K | --0 | --0 | ---259.71K | ---- | --0 | --0 | --0 | --0 | ---- |
-Less:Other special charges | --259.71K | --0 | ---- | --259.71K | ---- | ---- | ---- | ---- | ---- | ---- |
Other non- operating income (expenses) | -81.67%354.49K | -58.73%299.86K | 559.73%96.06K | -95.35%50.13K | -180.68%-91.56K | 957.00%1.93M | 462.80%726.65K | -69.47%14.56K | 594.46%1.08M | 149.70%113.49K |
Income before tax | 773.17%67.32M | 691.64%27.73M | 1,243.93%17.61M | 1,070.27%13.58M | 383.83%8.4M | 120.28%7.71M | 434.67%3.5M | -69.92%1.31M | 107.70%1.16M | 106.21%1.74M |
Income tax | -1,932.45%-11.21M | 319.19%2.36M | 13,525.99%2.16M | -78,650.19%-16.12M | 3,281.74%393.09K | 780.51%611.49K | 2,606.22%563.46K | 46.61%15.87K | 23.26%20.53K | -45.03%11.62K |
Net income | 1,006.26%78.52M | 763.04%25.37M | 1,093.31%15.45M | 2,505.94%29.7M | 364.30%8.01M | 118.63%7.1M | 363.39%2.94M | -70.21%1.29M | 107.56%1.14M | 106.16%1.72M |
Net income continuous Operations | 1,006.26%78.52M | 763.04%25.37M | 1,093.31%15.45M | 2,505.94%29.7M | 364.30%8.01M | 118.63%7.1M | 363.39%2.94M | -70.21%1.29M | 107.56%1.14M | 106.16%1.72M |
Minority interest income | ||||||||||
Net income attributable to the parent company | 1,006.26%78.52M | 763.04%25.37M | 1,093.31%15.45M | 2,505.94%29.7M | 364.30%8.01M | 118.63%7.1M | 363.39%2.94M | -70.21%1.29M | 107.56%1.14M | 106.16%1.72M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | 1,006.26%78.52M | 763.04%25.37M | 1,093.31%15.45M | 2,505.94%29.7M | 364.30%8.01M | 118.63%7.1M | 363.39%2.94M | -70.21%1.29M | 107.56%1.14M | 106.16%1.72M |
Basic earnings per share | 1,000.79%2.33 | 769.23%0.7533 | 1,113.05%0.465 | 2,525.03%0.875 | 354.84%0.235 | 118.14%0.2117 | 300.00%0.0867 | -71.25%0.0383 | 107.22%0.0333 | 105.97%0.0517 |
Diluted earnings per share | 950.40%2.1883 | 721.57%0.6983 | 1,039.14%0.4367 | 2,365.03%0.8217 | 332.25%0.2233 | 117.86%0.2083 | 292.30%0.085 | -68.49%0.0383 | 107.22%0.0333 | 105.97%0.0517 |
Dividend per share | ||||||||||
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |